Company Description
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases.
Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants.
The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria; and VAX-XL, a third-generation pneumococcal conjugate vaccine.
The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020.
Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
| Country | United States |
| Founded | 2013 |
| IPO Date | Jun 12, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 507 |
| CEO | Grant Pickering |
Contact Details
Address: 825 Industrial Road, Suite 300 San Carlos, California 94070 United States | |
| Phone | 650 837 0111 |
| Website | vaxcyte.com |
Stock Details
| Ticker Symbol | PCVX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 1649094 |
| CUSIP Number | 92243G108 |
| ISIN Number | US92243G1085 |
| Employer ID | 46-4233385 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Grant E. Pickering M.B.A. | Co-Founder, Chief Executive Officer and Director |
| Andrew L. Guggenhime M.B.A. | President and Chief Financial Officer |
| James T. Wassil M.B.A., M.S. | Executive Vice President and Chief Operating Officer |
| Dr. Jeff Fairman Ph.D. | Co-Founder and Vice President of Research |
| Elvia Cowan | Senior Vice President of Finance and Chief Accounting Officer |
| Jeff Macdonald | Executive Director of Investor Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 9, 2026 | 144 | Filing |
| Sep 4, 2026 | 144 | Filing |
| Sep 3, 2026 | 8-K | Current Report |
| Sep 1, 2026 | 144 | Filing |
| Aug 11, 2026 | SCHEDULE 13G/A | Filing |
| Aug 7, 2026 | SCHEDULE 13G/A | Filing |
| Aug 6, 2026 | SCHEDULE 13G/A | Filing |
| Aug 5, 2026 | 10-Q | Quarterly Report |
| Aug 5, 2026 | 8-K | Current Report |
| Aug 5, 2026 | 144 | Filing |